#Genome Analysis

Join us for the latest episode of Tomorrow’s Cure where experts from Inflection Medicine, Rady Children’s Institute for Genomic Medicine and Mayo Clinic discuss the impact of rapid whole genome sequencing in pediatric care. ⁣ ⁣ Learn how genomics is changing the diagnostic journey for every child. Watch now - link in our bio.

For many families living with a rare disease, the hardest part is not just the symptoms. It is the waiting. The unanswered questions. The quiet after yet another appointment without clarity. On Rare Disease Day, we are sharing a different part of the story. 🧬 In our latest blog, we explore how a single genomic answer can change everything. At the HudsonAlpha Institute for Biotechnology in Huntsville, whole genome sequencing is helping families move from uncertainty to understanding. But the impact does not stop there. A diagnosis can mean access to specialists. It can open doors to clinical trials. It can connect families to others walking the same path. It can even shape research and state and national policy, improving care for the next child still searching for answers. One diagnosis does more than name a condition. It creates ripples that strengthen homes, build communities, and advance research around the world. 💙🔬 #Discovery #GenomicMedicine #RareDiseaseAwareness #HudsonAlpha #PrecisionMedicine

A Child’s DNA rewritten: World-First Personalized CRISPR Therapy for CPS1 Deficiency For the first time in history, doctors didn’t just treat a genetic disease—they rewrote it inside a living child. In this episode of The Future of You: Human Biology Updates & Discoveries, we explore a groundbreaking medical milestone: a child with CPS1 deficiency successfully treated using a customized in vivo CRISPR base editing therapy delivered through lipid nanoparticles. This world-first treatment used a personalized gene-editing approach based on CRISPR technology to precisely correct a mutation in the CPS1 gene, responsible for a rare and life-threatening urea cycle disorder. Unlike traditional therapies, this intervention directly edited DNA inside the patient’s body—without removing cells for modification. In this video, you’ll learn: • What CPS1 deficiency is and why it’s dangerous • How in vivo base editing works • Why lipid nanoparticles are critical for gene delivery • The difference between CRISPR cutting and base editing • What this breakthrough means for the future of personalized medicine This case could mark the beginning of truly individualized genetic therapies—where treatments are designed for a single patient’s unique mutation. Sources & Further Reading 🔗 U.S. National Library of Medicine – CRISPR-Cas Systems Overview https://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/ 🔗 National Human Genome Research Institute – Genome Editing & CRISPR https://www.genome.gov/about-genomics/policy-issues/Genome-Editing 🔗 National Organization for Rare Disorders – CPS1 Deficiency https://rarediseases.org/rare-diseases/carbamoyl-phosphate-synthetase-i-deficiency/ 🔗 Nature – Base Editing Technology Overview https://www.nature.com/articles/nature17946 #CRISPR #GeneEditing #PersonalizedMedicine #BiotechBreakthrough #GenomeEditing #MedicalInnovation #RareDisease #FutureOfMedicine #BaseEditing #HumanBiology

a landmark medical development, researchers have reported a major breakthrough in gene-editing therapy aimed at treating inherited genetic disorders. Scientists successfully used advanced CRISPR-based gene editing techniques to correct faulty genes responsible for specific hereditary conditions in controlled clinical settings. The treatment works by precisely targeting and modifying defective DNA sequences within affected cells. By repairing the genetic mutation at its source, the therapy aims to prevent the production of abnormal proteins that cause disease symptoms. Early clinical trial data shows significant improvement in patients who previously had limited treatment options. The procedure was conducted under strict medical supervision with comprehensive genetic screening and monitoring protocols. Researchers emphasized that while the early results are promising, long-term safety and broader trials are still ongoing before widespread adoption can occur. Experts believe this advancement could open new possibilities in treating conditions such as blood disorders, metabolic syndromes, and other inherited diseases. Regulatory review and extended patient follow-ups will determine the next phase of this groundbreaking medical innovation.

When something is rare, the journey can feel isolating. For many families, the hardest part is not just the symptoms, but the uncertainty. The unanswered questions. The years of searching. This Rare Disease Day, MedGenome stands with every patient and every family navigating that path. MedGenome’s advanced genomic diagnostics can help uncover the underlying genetic cause, bringing clarity, direction, and a starting point for care. Because rare does not mean alone. And it should never mean invisible. To know more: 📞 1800 296 9696 or click the link in bio. #CarefortheRare #RareDiseaseDay #RareButNotAlone #GenomicDiagnostics #RareDiseaseAwareness #ClinicalGenomics #PrecisionMedicine #GeneticTesting #UndiagnosedDiseases #Medgenome

Is primary care ready for genetics? Primary care or family medicine practices can utilize the genetics the same way they use other specialties like cardiology or radiology. Natasha talks about putting an “easy button” in electronic medical record systems to streamline getting patients into genetics. 👀Watch the full episode on YouTube 🎧Listen on Apple, Spotify or wherever you get podcasts! Have you talked to your primary care doc about genetic testing? Answer below! 👇 #PrimaryCare #GeneticServices #GeneticsInHealthcare #PrecisionHealth #GeneChat #FamilyMedicine #InternalMedicine #GeneticTesting #MainstreamGenetics #GeneticsExplained #PersonalizedCare #HealthcarePodcast

Consistency matters when you’re trying to piece together answers to questions that have been unsolved for years. Nate shares how they have overcome inherent data analysis issues to accelerate their journey characterising rare diseases. 🔗 Learn more through the link in bio. Oxford Nanopore technology is for research use only.

The First Personalized Gene Therapy: A Baby’s Life Transformed 2026 Breakthrough A groundbreaking moment in medical history: the world’s first personalized gene editing therapy has helped a child with a rare genetic disorder take his first steps. This video explores how scientists are now building a scalable platform to bring these life saving treatments to thousands of families. Disclaimer: AI generated visuals. Not medical advice. Based on verified reporting. Sources: MIT Technology Review — “Three technologies that will shape biotech in 2026” (Jan 16, 2026), Aurora Therapeutics — “Aurora Therapeutics Launches…” (Jan 9, 2026), STAT News — Coverage on personalized gene therapy trials (Jan 2026).

Happy Rare Disease Day! 🤍🦓🖤 To celebrate, we chatted with genetic experts in Brazil 🇧🇷🧬 We learn how rare diseases are diagnosed and managed in Brazil, the challenges families face compared to the U.S., and how whole genome sequencing is accelerating answers. Featuring insights from Neogenomica’s Dr. João Bosco Oliveira and MGI’s Victor Camillo, this conversation highlights the power of genomics and global collaboration in rare disease care. 🎧Stream Episode 383 in your fav podcast app by searching “DNA Today” or use the links in our bio. #RareDiseaseDay #RareDiseaseBrazil #RareDiseases #WholeGenomeSequencing

Fellowship in Clinical Genetics transforms diagnosis into precision care, enabling early detection, accurate decisions, and stronger family counseling. #fellowshipincritical Fellowship in Clinical Genetics equips doctors to interpret complex genetic reports, identify inherited risks, and guide families with clarity. From rare disorders to hereditary cancers, advanced genomic training strengthens early diagnosis and personalized treatment strategies. #precisionmedicine #medicaleducation #genomicmedicine #doctorscareer

Whole genome sequencing is technically complex. But in unresolved rare diseases, after panels and inconclusive exomes, the real challenge becomes interpretation. GENOME FULL is an interpretation-intensive analysis, designed for when standard tests fail. Data do not make decisions. People do. And responsibility follows. Il whole genome sequencing è tecnicamente complesso. Ma nei casi di malattie rare irrisolte, dopo pannelli ed esomi non conclusivi, la vera difficoltà diventa l’interpretazione. GENOME FULL è un’analisi interpretation-intensive, pensata per quando i test standard falliscono. Perché i dati non decidono. Le decisioni sì. E con esse, la responsabilità. #genomics #rarediseases #wholegenomesequencing #wholeexomesequencing #clinicalgenetics

Dr. Massart discusses why primary care is ready for genetics and how patients bring up questions related to genetic testing to their doctors. Learn more about how Dr. Massart and Natasha integrated genetics into primary care in our latest All Access DNA episode. Watch on YouTube Listen on Spotify, Apple, or wherever you get podcasts #PrimaryCare #GeneticServices #GeneticsInHealthcare #PrecisionHealth #GeneChat #FamilyMedicine #InternalMedicine #GeneticTesting #MainstreamGenetics #GeneticsExplained #PersonalizedCare #HealthcarePodcast